<DOC>
	<DOCNO>NCT01564784</DOCNO>
	<brief_summary>This study compare efficacy , term complete response overall survival , inotuzumab ozogamicin versus investigator 's choice chemotherapy .</brief_summary>
	<brief_title>A Study Of Inotuzumab Ozogamicin Versus Investigator 's Choice Of Chemotherapy In Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<criteria>CD22 expression Adequate liver renal function Isolated extramedullary disease Active Central Nervous System [ CNS ] disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>